A 64‐year‐old woman presented with non‐neutropenic fever and back pain one day after the first cycle of neoadjuvant chemotherapy (doxorubicin–cyclophosphamide) for locally advanced breast cancer. She had also received pegylated granulocyte colony stimulating factor (PEG‐GCSF) one day after chemotherapy to enable dose‐dense chemotherapy scheduling. She was originally treated with intravenous antibiotics and discharged home on oral amoxicillin–clavulanate, with improvement in symptoms.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Pugh D, Grayson P, Basu N, Dhaun N. Aortitis: recent advances, current concepts and future possibilities. Heart 2021; 107: 1620–1629.
- 2. Murphy DJ, Keraliya AR, Agrawal MD, et al. Cross‐sectional imaging of aortic infections. Insights Imaging 2016; 7: 801–818.
- 3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient‐level meta‐analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440–1452.
- 4. Hoshina H, Takei H. Granulocyte‐colony stimulating factor‐associated aortitis in cancer: a systematic literature review. Cancer Treat Res Commun 2021; 29: 100454.
- 5. Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol 2021; 73: 1349–1365.
Patient consent:
The patient gave written consent for publication.
Prudence Francis received an honorarium for giving a lecture at a meeting organised by Eli Lilly.